期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

基于细胞凋亡机制的抗肿瘤药物研究进展 被引量：1

Recent advance of apoptosis based anti-tumour drugs
原文传递
导出
摘要 基于细胞凋亡机制的抗肿瘤药物的研究是发现新型抗肿瘤药物的重要策略。该机制中与肿瘤发生和发展相关的有死亡受体、Bc l-2家族、IAP家族、MDM2蛋白等,该文对近年来以这些蛋白和受体为靶标的抗肿瘤药物研究进展进行综述。 It is one of the most important strategy to discover novel anti-tumour drugs based on apoptosis mechanism. This review will highlight recent advances on the design and development of novel anti-tumour drugs targeting the death receptors,Bcl-2 family proteins,inhibitor of apoptosis proteins and MDM2 protein in the apoptosis pathway.
作者 马小根 顾为 林汉森 聂爱华
机构地区 广东药学院药科学院 军事医学科学院毒物药物研究所
出处 《中国药物化学杂志》 CAS CSCD 2009年第4期293-307,共15页 Chinese Journal of Medicinal Chemistry
基金 国家自然科学基金项目(30873136)
关键词 细胞凋亡 抗肿瘤药物 死亡受体 BCL-2家族蛋白 IAP家族蛋白 MDM2蛋白 抑制剂 apoptosis anti-tumour drag death receptor Bcl-2 family protein inhibitor of apoptosis proteins MDM2 protein inhibitor
分类号 R979.1 [医药卫生—药品]
  • 相关文献

参考文献52

  • 1ZIEGLER D S, KUNG A L. Therapeutic targeting of apoptosis pathways in cancer[ J]. CUlT Opin Oncol, 2008,20( 1 ) :97 - 103.
  • 2ASHKENAZI A. Directing cancer cells to self-destruct with pro-apoptotic receptor agonists [ J ]. Nat Rev Drug Discov,2008,7 (12) : 1001 - 1012.
  • 3ASHKENAZI A, HERBST R S. To kill a tumor cell: the potential of proapoptotic receptor agonists [ J ]. J Clin Invest,2008,118 ( 6 ) : 1979 - 1990.
  • 4SORIA J,SMrr D,KHAYAT B,et al. Phase Ib study of recombinant human(rh) Apo2L/TRAIL in combination with paclitaxel, carboplatin, and bevacizumab ( PCB ) in patients (pts) with advanced non-small cell lung cancer(NSCLC) [ J]. 3 Clin Oncol Abstr, 2008,26 ( Suppl. ) :3539.
  • 5OLDENHIJIS C, MOM C, SLELIFER S, et al. A phase I study with the agonistic TRAIL-R1 antibody, mapatumumab,in combination with gemcitabine and cisplatin [ J ]. J Clin Oncol Abstr,2008,26 ( Suppl. ) : 3540.
  • 6PATNAIK A, WAKELEE H,MITA M,et al. HGS- ETR2-A fully human monoclonal antibody to TRAIL-R2:rcsults of a phase Ⅰ trial in patients with advanced solid tumors [ J ]. J Clin Oncol, 2006,24 (Suppl. 18) :3012.
  • 7SHARMA S, VRIES E G, INFANTE J R, et al. Phase I trial of LBY135 ,a monoclonal antibody agonist to DR5, alone and in combination with capecitabine in advanced solid tumors[J]. J Clin Oncol Abstr,2008,26( Suppl. ) :3538.
  • 8SALEH M N, PERCENT T E, WOOD J, et al. A phaseⅠ study of CS-1008 ( humanized monoclonal antibody targeting death receptor 5 or DR5 ), administered weekly to patients with advanced solid tumors or lymphomas [ J]. J Clin Oncol Abstr, 2008, 26 (Suppl.) :3537.
  • 9SATTLER M, LIANG H, NETTESHEIM D, et al.Structure of Bcl-XL-Bak peptide complex:recognition between regulators of apoptosis [ J ]. Science, 1997,275 (5302) :983 - 986.
  • 10LEE E F,CZABOTAR P E,SMITH B J,et al. Crystal structure of ABT-737 complexed with Bcl-XL: implications for selectivity of antagonists of the Bcl- 2 family [ J ]. Cell Death Differ, 2007, 14 ( 9 ) : 1711 -1713.

同被引文献8

引证文献1

二级引证文献2

中国药物化学杂志
2009年 第4期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部